EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants

Md Saqline Mostaq iD, Mohammad N Amin iD, Amanda Raphael, Celine Asbury, Anish Gupta, Xin Gu, Xianlin Han iD, Davorka Sekulic, Pawel Michalak, Lin Kang, Yong-Yu Liu iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27073237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Md Saqline Mostaq und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA. Hauptthemen laut MEDLINE: Glucosyltransferases, Drug Resistance, Neoplasm, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucosylceramide synthase (GCS) catalyzes ceramide glycosylation in response to cell stress that produces glucosylceramide and other glycosphingolipids. GCS overexpression is a cause of drug resistance and enriches cancer stem cells (CSCs) during cancer chemotherapy. Previous studies showed that GCS modulates the expression of p53 mutants and oncogenic gain-of-function (GOF) in heterozygous knock-in cell models (TP53 R273H−/+). However, it is unclear whether GCS can modulate the effects of homozygous p53 mutations, which are common in many cancer cases. We report herewith that inhibition of GCS, via UGCG knockout and using an inhibitor (Genz-161), effectively re-sensitizes drug resistance and diminishes CSCs in colon cancer cells carrying the homozygous p53 R273H mutation. In aggressive WiDr cells carrying TP53 R273H mutation, knockout of UGCG gene using CRISPR/Cas9 editing or inhibition of GCS with Genz-161 sensitized cancer cells to oxaliplatin, irinotecan and paclitaxel. With decreased ceramide glycosylation in lipidomic profiling, both UGCG knockout and Genz-161 treatments substantially decreased wound healing, and diminished CSCs and tumor growth under chemotherapy. Interestingly, inhibition of RNA m6A methylation by neplanocin A markedly increased p53 function and reversed drug resistance. Mechanistic investigation revealed that GCS inhibition downregulated methyltransferase-like 3 (METTL3) expression and decreased RNA-m6A modification on mutant p53 R273H effects. Altogether, our findings demonstrate that ceramide glycosylation promotes METTL3 expression and RNA m6A methylation in response to drug-induced stress, thereby promoting mutant p53 expression and associated GOF. Conversely, inhibition of GCS can diminish CSCs and drug resistance via reduction in m6A modification and advance of p53-assocaited tumor suppressive function. GCS inhibition is an achievable approach for mutant cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosyltransferasesDrug Resistance, NeoplasmTumor Suppressor Protein p53MutationHumansCell Line, TumorNeoplastic Stem CellsAnimalsAntineoplastic AgentsHomozygoteGene Expression Regulation, NeoplasticPaclitaxelOxaliplatinMice

Stichwörter der Autor:innen

N6-methyladenosineRNA modificationcancer stem cellsdrug resistanceglucosylceramide synthasemissense mutationp53 tumor suppressor

Substanzen

Glucosyltransferasesceramide glucosyltransferaseTumor Suppressor Protein p53Antineoplastic AgentsTP53 protein, humanPaclitaxelOxaliplatin

Autor:innen und Institutionen

  • School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.
  • Division of Biomedical Affairs and Research, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA.
  • Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 70112, USA.
  • Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX 78229, USA.
  • Global Medical Affairs, RD Hematology, Sanofi, Cambridge, MA 02139, USA.
  • Center for One Health Research, VA-MD College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA.

ORCID-Profile: Md Saqline Mostaq, Mohammad N Amin, Xianlin Han, Yong-Yu Liu

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Institute of General Medical Sciences
  • National Cancer Institute
  • Edward Via College of Osteopathic Medicine-Louisiana Campus
  • Mizutani Foundation for Glycoscience

Zitieren

APA

Mostaq, M. S., Amin, M. N., Raphael, A., Asbury, C., Gupta, A., Gu, X., Han, X., Sekulic, D., Michalak, P., Kang, L., & Liu, Y. Y. (2026). Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073237

Vancouver

Mostaq MS, Amin MN, Raphael A, Asbury C, Gupta A, Gu X, et al. Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27073237

BibTeX
@article{Mostaq2026,
  author = {Mostaq, Md Saqline and Amin, Mohammad N and Raphael, Amanda and Asbury, Celine and Gupta, Anish and Gu, Xin and Han, Xianlin and Sekulic, Davorka and Michalak, Pawel and Kang, Lin and Liu, Yong-Yu},
  title = {Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27073237}
}
Kostenlos starten →